Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2021 6
2022 3
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Omicron subvariants illustrate reduced respiratory tissue penetration, cell damage and inflammatory responses in human airway epithelia.
Zaderer V, Abd El Halim H, Wyremblewsky AL, Lupoli G, Dächert C, Muenchhoff M, Graf A, Blum H, Lass-Flörl C, Keppler OT, Huber LA, Posch W, Wilflingseder D. Zaderer V, et al. Front Immunol. 2023 Oct 17;14:1258268. doi: 10.3389/fimmu.2023.1258268. eCollection 2023. Front Immunol. 2023. PMID: 37915577 Free PMC article.
Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern.
Diem G, Dichtl S, Zaderer V, Lass-Flörl C, Reindl M, Lupoli G, Dächert C, Muenchhoff M, Graf A, Blum H, Keppler OT, Wilflingseder D, Posch W. Diem G, et al. Among authors: zaderer v. Microbiol Spectr. 2023 Aug 8;11(5):e0179323. doi: 10.1128/spectrum.01793-23. Online ahead of print. Microbiol Spectr. 2023. PMID: 37551989 Free PMC article.
Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation.
Dichtl S, Diem G, Jäger M, Zaderer V, Lupoli G, Dächert C, Muenchhoff M, Graf A, Blum H, Keppler OT, Lass-Flörl C, Weiss G, Wilflingseder D, Posch W. Dichtl S, et al. Among authors: zaderer v. Antiviral Res. 2023 May;213:105581. doi: 10.1016/j.antiviral.2023.105581. Epub 2023 Mar 23. Antiviral Res. 2023. PMID: 36965526 Free PMC article.
Guidelines for visualization and analysis of DC in tissues using multiparameter fluorescence microscopy imaging methods.
Bayerl F, Bejarano DA, Bertacchi G, Doffin AC, Gobbini E, Hubert M, Li L, Meiser P, Pedde AM, Posch W, Rupp L, Schlitzer A, Schmitz M, Schraml BU, Uderhardt S, Valladeau-Guilemond J, Wilflingseder D, Zaderer V, Böttcher JP. Bayerl F, et al. Among authors: zaderer v. Eur J Immunol. 2023 Nov;53(11):e2249923. doi: 10.1002/eji.202249923. Epub 2023 Jan 9. Eur J Immunol. 2023. PMID: 36623939
Inhalation of Low Molecular Weight Heparins as Prophylaxis against SARS-CoV-2.
Eder J, Bermejo-Jambrina M, Vlaming KE, Kaptein TM, Zaderer V, Kemper EM, Wilflingseder D, Reitsma S, de Bree GJ, Cohn DM, Geijtenbeek TBH. Eder J, et al. Among authors: zaderer v. mBio. 2022 Dec 20;13(6):e0255822. doi: 10.1128/mbio.02558-22. Epub 2022 Nov 3. mBio. 2022. PMID: 36326251 Free PMC article.
Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections.
Dichtl S, Zaderer V, Kozubowski V, Abd El Halim H, Lafon E, Lanser L, Weiss G, Lass-Flörl C, Wilflingseder D, Posch W. Dichtl S, et al. Among authors: zaderer v. Front Med (Lausanne). 2022 Sep 29;9:1005589. doi: 10.3389/fmed.2022.1005589. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36250084 Free PMC article.
17 results